Literature DB >> 22709522

Nonhuman primate models of encephalitic alphavirus infection: historical review and future perspectives.

Lesley C Dupuy1, Douglas S Reed.   

Abstract

Venezuelan, western, and eastern equine encephalitis viruses are New World alphaviruses that are recognized as potential agents of biowarfare and bioterrorism owing to their morbidity and mortality in humans, ease of production, considerable stability, and high infectivity in aerosols. As a result, these encephalitic alphaviruses are defined as category B select agents. Studies involving infection of nonhuman primates have been instrumental in gaining an understanding of the in vivo pathogenesis of these viruses and have provided relevant models to evaluate the efficacy of candidate human vaccines. Recent advances have led to refinement and further characterization of these models toward the goal of utility in the licensure of next-generation alphavirus vaccines and therapeutics for use in humans by the Animal Rule.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22709522     DOI: 10.1016/j.coviro.2012.02.014

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  7 in total

1.  Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial.

Authors:  Emily E Coates; Srilatha Edupuganti; Grace L Chen; Myra Happe; Larisa Strom; Alicia Widge; Maria Burgos Florez; Josephine H Cox; Ingelise Gordon; Sarah Plummer; Abidemi Ola; Galina Yamshchikov; Charla Andrews; Sharon Curate-Ingram; Patricia Morgan; Shashi Nagar; Matthew H Collins; Amy Bray; Thuy Nguyen; Judy Stein; Christopher L Case; Florence Kaltovich; Diane Wycuff; C Jason Liang; Kevin Carlton; Sandra Vazquez; John R Mascola; Julie E Ledgerwood
Journal:  Lancet Infect Dis       Date:  2022-05-11       Impact factor: 71.421

2.  Long-term persistence of viral RNA and inflammation in the CNS of macaques exposed to aerosolized Venezuelan equine encephalitis virus.

Authors:  Henry Ma; Joseph R Albe; Theron Gilliland; Cynthia M McMillen; Christina L Gardner; Devin A Boyles; Emily L Cottle; Matthew D Dunn; Jeneveve D Lundy; Noah Salama; Katherine J O'Malley; Ivona Pandrea; Tobias Teichert; Stacey Barrick; William B Klimstra; Amy L Hartman; Douglas S Reed
Journal:  PLoS Pathog       Date:  2022-06-13       Impact factor: 7.464

3.  A chimeric Sindbis-based vaccine protects cynomolgus macaques against a lethal aerosol challenge of eastern equine encephalitis virus.

Authors:  Chad J Roy; A Paige Adams; Eryu Wang; Grace Leal; Robert L Seymour; Satheesh K Sivasubramani; William Mega; Ilya Frolov; Peter J Didier; Scott C Weaver
Journal:  Vaccine       Date:  2013-01-16       Impact factor: 3.641

4.  Designing multivalent immunogens for alphavirus vaccine optimization.

Authors:  C M Read; Kenneth Plante; Grace Rafael; Shannan L Rossi; Werner Braun; Scott C Weaver; Catherine H Schein
Journal:  Virology       Date:  2021-02-05       Impact factor: 3.513

5.  Electrocardiography Abnormalities in Macaques after Infection with Encephalitic Alphaviruses.

Authors:  Henry Ma; Jeneveve D Lundy; Katherine J O'Malley; William B Klimstra; Amy L Hartman; Douglas S Reed
Journal:  Pathogens       Date:  2019-11-16

6.  Therapeutic monoclonal antibody treatment protects nonhuman primates from severe Venezuelan equine encephalitis virus disease after aerosol exposure.

Authors:  Crystal W Burke; Jeffery W Froude; Franco Rossi; Charles E White; Crystal L Moyer; Jane Ennis; M Louise Pitt; Stephen Streatfield; R Mark Jones; Konstantin Musiychuk; Jukka Kervinen; Larry Zeitlin; Vidadi Yusibov; Pamela J Glass
Journal:  PLoS Pathog       Date:  2019-12-02       Impact factor: 6.823

Review 7.  Live Viral Vaccine Neurovirulence Screening: Current and Future Models.

Authors:  Corey May Fulton; Wendy J Bailey
Journal:  Vaccines (Basel)       Date:  2021-06-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.